Journal of Biomedical and Pharmaceutical Research
Available Online at www.jbpr.in
CODEN: - JBPRAU (Source: - American Chemical Society)
NLM (National Library of Medicine): ID: (101671502)
Index Copernicus Value 2023: 85.868
Volume 14, Issue 2; 2025, 09-18

ISSN (Online): 2279-0594
ISSN (Print): 2589-8752

Review Article

Revolutionizing Cancer Treatment: The Role of Nanotechnology in Breast and Colorectal Cancer

T. Premdas[1], A. Vennela[2], G. Tejashwini[3]

[1, 2, 3]B.Pharmacy 4th Year Students, Anurag Pharmacy College, Kodad, Telangana

Article Info: Received: 11-01-2025 / Revised: 19-02-2025 / Accepted: 09-03-2025
Corresponding Author: T. Premdas
DOI: https://doi.org/10.32553/jbpr.v14i2.1254
Conflict of interest statement: No conflict of interest

Abstract:
Cancer remains a leading cause of mortality worldwide, with breast and colorectal cancers among the most prevalent. Despite advancements in conventional treatments such as chemotherapy, radiation therapy, and immunotherapy, challenges like systemic toxicity, drug resistance, and lack of targeted therapy persist. Nanotechnology has emerged as a promising approach in oncology, offering precise drug delivery, improved bioavailability, and reduced side effects. This review explores the role of nanotechnology in breast and colorectal cancer treatment, focusing on recent advancements in drug delivery, targeted therapy, imaging, and diagnostics. A comprehensive literature review highlights the potential of nanoparticles in enhancing drug solubility, improving tumor targeting, and minimizing systemic toxicity. Additionally, multifunctional nanoparticles have shown promise in delivering chemotherapy, genetic material, and immune-modulating agents with high specificity. Imaging applications using nanoparticles have also advanced early cancer detection and treatment monitoring. While nanotechnology presents transformative potential in oncology, challenges such as biocompatibility, large-scale production, and regulatory approvals must be addressed before widespread clinical application. Continued research and innovation in nanomedicine could lead to more effective and personalized cancer therapies.
Keywords: Nanotechnology, Breast Cancer, Colorectal Cancer, Drug Delivery, Targeted Therapy, Nanomedicine, Nanoparticles, Cancer Imaging, Immunotherapy, Gene Therapy.

Introduction

Every tissue contains abnormal cells that reproduce endlessly while spreading between tissues which constitutes the disorders known as cancer. Breast and colon cancers represent the most severe types of malignancies since they multiply as the two leading dangerous cancers affecting human lives globally. The clinical methods of chemotherapy and radiation therapy typically lead to serious negative outcomes since they lack precision and create systemic damage that results in drug resistance. Nanotechnology represents the current leading medical research approach because it helps eliminate destructive side effects from medical treatments today. The nanoscale nature of nanotechnology enables cancer therapy development through effective drug delivery systems which boosts therapeutic efficacy while lowering side effects.

Nanotechnology in Cancer Therapy

The use of nanotechnology includes designing materials and devices through production steps

which generate engineering properties from nanoscale dimensions between 1-100 nm (1-100 nm). The interaction capabilities of nanoparticles with biological systems stem from their small size and unique characteristics which makes them optimal for cancer treatment applications. [1].

Nanoparticles function both as delivery systems for drugs and image-enhancing agents as well as targeted therapeutic platforms. The precise delivery of nanoparticles to specific tissues along with tumor sites assists in minimizing drug effects on incorrect targets which leads to enhanced therapeutic drug ratios. Nanoparticles enhance drug delivery when used to adjust drug characteristics of solubility along with stability and bioavailability. Nanotechnology integration with cancer treatment methods is predicted to reform cancer therapy practices [2].

Various nanoparticle categories such as magnetic nanoparticles and carbon nanotubes and polymeric micelles and liposomes have been employed for cancer detection and imaging applications because of their multiple biological applications. Multiple medical applications take advantage of nanomaterials because of their essential characteristics. Nanomaterials show special chemical properties along with optical and magnetic and chemical properties that enable researchers to develop imaging probes which provide advanced contrast and sensitivity and targeted biodistribution and improved spatial imaging capabilities for MRI and PET and SPECT and ultrasound imaging methods [3].

Methodology

A thorough review of recent literature was conducted, examining various nanotechnology-based approaches such as nanoparticles for drug delivery, gene therapy, immunotherapy, and theranostics. The research utilized multiple databases, including Google Scholar, NLM, and Web of Science, to gather relevant studies and advancements in the field.

Discussion:

Fundamentals of Nanoparticles in Cancer Therapy

1. **Nanoparticle Design and Properties:**

Typically, 1 to 100 nm in diameter, nanoparticles are engineered to better interact with biological systems. Through the enhanced permeability and retention (EPR) affect characteristic of tumor vasculature, their small dimensions enable tumor passive targeting. Thus, nanoparticles tend to accumulate more readily in tumor tissue. Surface modification of nanoparticles can further increase nanoparticles' stability, solubility, and cell absorption [4, 5].

2. **Drug Delivery and Targeting:**

Nanoparticles function as carriers to deliver chemotherapy medications and genes and therapeutic substances precisely to tumor locations. Through active targeting cancer cells become specific targets for nanoparticles which are directed to cancer cells by attaching ligands such as peptides or antibodies to their surfaces. This delivery technique sends medications directly to tumors while creating the smallest amount of harm to healthy tissues which enhances therapeutic effectiveness [6].

3. **Thermal and Photodynamic Therapy:**

Gold nanoparticles function as an example of nanoparticles that absorb light energy to generate localized heat which destroys cancer cells. Photodynamic therapy activates specific nanoparticles that produce reactive oxygen species which directly harm cancer cells. These treatments deliver precise therapy because they protect healthy tissues that surround the treatment area [7].

4. **Gene Delivery:**

The genetic materials like plasmid DNA and short interfering RNA (siRNA), which may kill genes important in tumor growth, can be delivered by nanoparticles. Gene-based cancer treatments are made possible by these nanoparticles, which shield the genetic material from degradation and enable their effective transport into target cells [8].

5. **Biocompatibility and Safety:**

Nanoparticles need to be biocompatible, non-toxic, and biodegradable in order to be used in cancer treatment. Because they may safely decompose in the body without triggering strong immune reactions, biodegradable nanoparticles such as those derived from lipids or polymers are frequently chosen. This guarantees that nanoparticles cannot build up in tissues or become harmful over time.

Nanotechnology in Colorectal Cancer Treatment

Colorectal cancer (CRC) is one of the most common types of cancer in India and much more common in urban regions than it used to be. CRC, by and large, was believed to be primarily limited to the Western world; however, the number of such cases in India, related to urbanization, dietary changes, and changing lifestyles, has increased tremendously. Several factors have contributed to this increasing incidence of CRC in India, like the consumption of a high-fat diet, low dietary fiber, lack of exercise, and increased consumption of processed food [9]. Colorectal cancer happens to be one of the leading contributors to deaths worldwide, and in Correspondence with data obtained, In India, the sudden mushrooming of colorectal cancer is a public health problem due to an approximate of 27,000 new cases and 19,000 deaths from colorectal cancer in a year [10]. Subtypes include:

1. Microsatellite instability-high (MSI-H): Identified by high levels of microsatellite instability.
2. Microsatellite stable (MSS): Identified by low levels of microsatellite instability.
3. Chromosomal instability (CIN): Identified by chromosomal instability.
4. CpG island methylator phenotype (CIMP): Identified by high levels of CpG island methylation.

1. **Targeted Drug Delivery**

Chemotherapeutic drug delivery to tumors while protecting normal organs from systemic toxicity stands as a main concern in treating cancer especially when treating colorectal cancer. The traditional chemotherapy drugs recognize both healthy cells and cancer cells which results in serious adverse reactions for patients. Nanoparticles possess dimensions within the range of 1-100 nm which allows them to utilize the Enhanced Permeability and Retention (EPR) effect to reach tumor tissue. Tumors have leaky blood vessels which allows nanoparticles to penetrate more easily than they can penetrate healthy tissues.

Nanoparticles can be designed with ligands including peptides and monoclonal antibodies and small compounds which specifically recognize receptors that are present in excess on colorectal cancer cells. Targeted drug delivery to cancer cells through this specific approach decreases damage to healthy tissues while boosting the drug's effectiveness.

The scientific community extensively investigates liposomes as colloidal drug delivery systems to treat colorectal cancer due to their spherical shape comprised of lipid bilayers. Liposomes receive the drug treatment directly to tumor sites through antibody functionalization that identifies colorectal cancer-specific antigens. The delivery system demonstrates prospects of making 5-fluorouracil (5-FU) treatment more effective as a major chemotherapy agent used against colorectal cancer [11].

2. **Improved Bioavailability and Solubility**

Most chemotherapeutics are poorly water soluble, limiting their absorption and efficacy. Encapsulation in nanocarriers improves solubility and bioavailability. Encapsulation stabilizes the drug and enables the possibility of achieving controlled and sustained release.

For example, the chemotherapeutic agent paclitaxel, which is commonly used for the treatment of colorectal cancer, has poor bioavailability and low solubility on intravenous administration. However, when nanoparticles encapsulate it, the solubility of paclitaxel is greatly enhanced, allowing a higher dose of drug

to reach the tumor. The controlled release of paclitaxel from the nanoparticles, in turn, ensures a sustained action of the drug in the body while maximizing the therapeutic effect and minimizing systemic toxicity. The remaining free paclitaxel is, however, susceptible to rapid metabolic clearance [12].

The nanoparticles offer a dual mechanism of action by combining many therapeutic compounds into a single nanocarrier. By targeting the tumor from several angles, this approach may increase the effectiveness of CRC therapy [13].

3. **Gene Therapy**

Gene therapy is a promising treatment option for colorectal cancer through the study of molecular mechanisms underlying carcinogenesis. These include mRNA, plasmid DNA and small interfering RNA. Certain genes responsible for tumor growth, metastasis or development of chemotherapy resistance can be inhibited, or their expression altered, using these genetic materials [14].

As an illustration, siRNA can be engineered to knock down genes responsible for drug resistance or overexpression of survival proteins in cancer cells. By being delivered through nanoparticles, siRNA will silence such genes, rendering the cancer cells vulnerable to standard chemotherapy. Particle application as gene therapy carriers facilitates efficient delivery of these molecules without degradation in the bloodstream and ensuring the therapeutic gene gets to the target cells [14].

Additionally, gene therapy can be used to strengthen the body's defenses against cancer. A possible combination therapy for better CRC management is provided by the use of nanoparticles to deliver immuno-modulatory substances which stimulate the immune system to become activated against CRC cells.

4. **Immunotherapy**

Immunotherapy is the latest treatment for cancer that tries to utilize the immune system to spot and destroy cancer cells. These nanoparticles reach the tumor site directly into the tumor and so are indispensable to immunotherapy. These nanoparticles may contain cytokines, cancer vaccines, or immune checkpoint blockers, and all exhibited promise in treating colorectal cancer [15].

For example, immune checkpoint inhibitors, such PD-1 inhibitors, which block the signals that stop T-cells from attacking cancer cells, can be delivered using nanoparticles. The efficiency of the immune response is increased and systemic adverse effects are decreased by employing nanoparticles to deliver these inhibitors straight to the tumor. Moreover, cancer vaccines that prime the immune system to identify and combat cancer cells can be delivered via nanoparticles. With the promise of longer-lasting effects and cure, this approach, called cancer immunotherapy, has been gaining popularity in the treatment of colorectal cancer [16].

5. **Thermal and Photodynamic Therapy**

The non-invasive treatments such as thermal and photodynamic therapy (PDT) can make nanoparticles possible. Employing nanoparticles that absorb light and convert it to heat upon exposure to infrared radiation is referred to as thermal treatment. By inducing hyperthermia, this local heating effect can potentially destroy cancer cells. For instance, gold nanoparticles are particularly beneficial in this case as they can preferentially target the cancer cells with minimal damage to healthy tissue through the absorption of near-infrared light and conversion to heat [17].

In PDT, photosensitizing agents are administered to the tumor through nanoparticles. These agents release reactive oxygen species (ROS) upon illumination, which damage and kill cancer cells. A strength of PDT is that it is a minimally invasive treatment that can be used in conjunction with other treatments to enhance the efficacy of each stage of treatment [18].

Nanoparticles for Imaging and Diagnosis in Colon Cancer:

Nanoparticles may also be utilized as diagnostic agents. Nanoparticles may be designed to incorporate imaging agents, e.g., fluorescent markers or contrast agents, to enable non-invasive imaging of tumors in situ. Detection of colon cancer early in its development is essential for effective treatment, and nanoparticles may enhance the sensitivity and specificity of imaging procedures, e.g., magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET). Iron oxide nanoparticles, for instance, have also been employed as contrast agents in MRI, where small colon cancer lesions have been detectable. Gold nanoparticles have also been investigated for their potential to facilitate signal amplification in different imaging modalities for improving the detection of colon tumors [19].

Nanoparticles used for Colon Cancer:

Nanoparticles used in cancer diagnosis and treatment are classified into two broad types: inorganic and organic. The electrical and optical properties of inorganic nanoparticles such as quantum dots, silica, carbon, and metallic nanoparticles lend themselves to the application of cancer imaging, whereas rapid degradation and stability are important for theranostics. Organic nanoparticles, such as lipid-based or macromolecular complexes, are relatively less stable, yet they exhibit almost perfect biocompatibility and offer excellent opportunities for biofunctionalization for drug delivery. Hybrid nanoparticles combine the biological advantages of organic nanoparticles with the advantages of strength provided by inorganic ones [20].

Nanotechnology in Breast Cancer Treatment:

Breast cancer is, available among women worldwide, among the most common and deadliest forms of cancer. It is the most common cancers among women and is one of the leading causes of cancer death in India. The causes of the rising incidence of this malignancy are attributed to lifestyle changes, urbanization, and delayed detection. Each subtype of the disease will require a different treatment approach, including:

1. **Luminal A:** Estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and human epidermal growth factor receptor 2-negative (HER2-)
2. **Luminal B:** ER+, PR+, and HER2+
3. **Triple-negative:** ER-, PR-, and HER2-
4. **HER2-positive:** HER2+ and ER- and/or PR- [21].

Surgery, chemotherapy, radiation, and hormonal therapy are only a few of the available treatment methods; but they frequently have serious side effects and limits, particularly when it comes to metastasis or drug resistance.

1. **Targeted Drug Delivery**

For instance, nanoparticles can now be designed to localize delivery of drugs to cancer cells with over expressed HER2 receptors which account for >20% of breast cancers, particularly HER2-positive breast cancer. Thus, drugs can be more efficiently and specifically delivered to the tumor by attaching ligands directly to the nanoparticles for targeting against HER2. Overall, this strategy improves delivery concentration while maximizing therapeutic efficacy and reducing off-target effects. This not only improves the concentration of the therapeutic agent at the tumor site, but also renders more bioavailable drugs that are poorly soluble or unstable. Functionalized drugs are targeting ligands, antibodies, peptides, or small molecules that bind specifically to the over expressed receptors on the cancer cells [22]. For example, Trastuzumab, an antibody that targets HER2, has been conjugated to nanoparticles to enhance its delivery to HER2-positive tumors and reduce off-target effects

2. **Improved Bioavailability and Solubility**

There is low solubility and hydrophobicity exhibited by several chemotherapeutic agents, such as doxorubicin and paclitaxel. This greatly impairs their absorption and the therapeutic efficacy of most intravenous chemotherapy. Solutions for these problems are available

through nanoparticles. These improve the solubility, stability, and bioavailability of the drugs. Nanoparticles may also serve as transporters and protect the encapsulated drug from destruction in the bloodstream to ensure that it reaches the intended area intact and in an active form [23].

Widespread examples of chemotherapy agents including doxorubicin and paclitaxel have been typically demonstrated to exhibit low solubility and hydrophobic properties; thereby, enabling a decrease in the absorption of intravenous therapy as well as its efficacy. Encapsulation of these drugs into nanoparticles can solve the problems by improving their solubility, stability, and bioavailability. Nanoparticles can also serve as carriers for the drug in its active state, protecting the encapsulated drug from degradation in the bloodstream [23].

For instance, apigenin is a simple flavonoid known for its anticancer activity against breast cancer cells. Its efficacy is diminished due to poor bioavailability and solubility. Thus, artificial nanomaterial-based delivery systems have been employed by researchers to overcome these barriers with an improvement in clinical bioavailability and solubility of apigenin through apigenin-loaded polymeric nanoparticles such as PLGA (polylactic-co-glycolic acid) and PEG (polyethylene glycol) nanoparticles, increased bioavailability and solubility of apigenin, inhibited breast cancer cell growth, and apoptosis induced [23].

3. Gene Therapy

Another emerging treatment method for cancer is gene therapy, which transfers genetic material into the cells, thereby affecting gene expression in an altered manner against the spread of a disease. Hence in developing gene therapy for breast cancer, nanotechnology plays a very important role in providing a specific and effective route of delivery for DNA plasmids, antisense oligonucleotides, or small interfering RNA (siRNA). The development of certain genes responsible for tumor formation, resistance to therapies, or metastasis can thus be inhibited by the interfering action of the therapeutic genetic agents mentioned above [24].

For instance, genes that participate in the PI3K/Akt/mTOR pathway, a widely used signaling system in breast cancer, may be targeted by siRNA to promote survival in cancer cells or provide treatment resistance. The therapeutic agents can be efficiently delivered into cancer cells and shielded from enzymatic degradation by nanoparticles. A more personalized treatment is facilitated by the ability to specifically target and silence specific genes, which addresses the underlying cause genetic origins of the disease [24].

4. Immunotherapy

Immunotherapy is a much-considered novel strategy that will give strength to the immune system in the fight against cancer. The immunotherapeutic means for breast cancer are intended to improve the immune system's capacity to detect and destroy tumor cells. Nanotechnology would markedly enhance the efficiency of these immunotherapies by localizing immune-modulating drugs at the tumor site

Nanoparticles can be used to deliver immune checkpoint inhibitor agents such as anti-PD-1 and anti-CTLA-4 antibodies, which have shown effectiveness in various malignancies, including breast cancer. Additional coatings on these nanoparticles with adjuvants or cancer vaccines can potentiate immune responses against the tumor [25].

Dendritic cell vaccines, which are designed to activate immune cells and prime them to attack cancer cells, can be delivered via nanoparticles for targeted delivery to immune cells. The controlled release of these immunotherapeutic agents ensures that the immune system is efficiently activated, potentially leading to improved outcomes in breast cancer treatment [26].

5. Thermal and Photodynamic Therapy

The nanoparticles can be employed in two new non-invasive therapeutic modalities that can be combined with conventional therapies: thermal therapy and photodynamic therapy (PDT). When exposed to infrared radiation, gold nanoparticles in thermal treatment absorb the light and transform it into heat, causing localized hyperthermia. Without causing harm to nearby healthy tissue, this targeted heating can specifically kill cancer cells. Nanoparticles can be used in photodynamic treatment to administer photosensitizing chemicals, which produce reactive oxygen species (ROS) when exposed to light, causing oxidative stress and ultimately the death of cancer cells. When used in combination with other treatment techniques like surgery or radiation therapy, this kind of therapy is very effective in treating superficial tumors. Both thermal and PDT therapies are minimally invasive and can be selectively activated, making them ideal for localized breast cancer treatment, especially in early-stage or small tumors [27].

Nanoparticles for Imaging and Diagnosis in Breast Cancer:

Similar to colon cancer, nanoparticles can also be utilized for imaging and diagnosis in breast cancer. Nanoparticles can be designed to carry imaging agents that allow for early detection of breast cancer and monitoring of treatment response. Magnetic nanoparticles and gold nanoparticles have been investigated for their ability to enhance the resolution of imaging techniques, such as MRI, Computed tomography (CT), Mammography (MG) and ultrasound [28].

Nanoparticles for Drug Delivery in Breast Cancer

The use of such chemotherapy agents, such as doxorubicin, paclitaxel, and docetaxel, limits treatment for breast cancer because their activity is usually accompanied by systemic toxicity toward normal healthy tissues. The use of drug delivery systems based on nanoparticles may enhance the delivery of these agents and thus potentially improve pharmacokinetics and biodistribution, leading to the reduction of systemic toxicity and the enhancement of therapeutic activity [29].

Polymeric nanoparticles (PEG-PCL), liposomes (Myocet), and dendrimers (Poly amidoamine) have been investigated for their ability to encapsulate and deliver chemotherapeutic agents specifically to breast cancer cells. Similarly, paclitaxel-loaded polymeric nanoparticles decorated with trastuzumab have demonstrated improved tumor targeting and reduced side effects compared to conventional paclitaxel therapy [30, 31].

Challenges and Future prospects

Nanoparticles are clearly becoming a potent means for treating colorectal and breast cancers by providing novel solutions to the disadvantages of conventional therapies, such as chemotherapy, radiation, and surgery. There are, however, a lot of issues that restrict their therapeutic application in cancer therapy. The foremost one is ensuring minimal toxicity and good biocompatibility. The other possibility is that it is possible that nanoparticles could facilitate targeted delivery of drugs, but with the possibility that such delivery may not always be desired due to the effect of biological systems. Long-term sequestration within organs, such as the liver and spleen, could limit their therapeutic potential, serving as a site for undesired immune activation, which in turn could bring about inflammatory or cytopathic effects. Another major obstacle is considered the complexity of nanoparticle production, as difficult and expensive manufacturing of nanoparticles meeting the high standards for clinical application is there. Reproducibility and quality control during nanoparticles production, such as liposomal formulation, are key to assuring reliable therapeutic outcomes. In addition, biodistribution and clearance of nanoparticles is yet a hurdle. In heterogeneous tumors, tumor heterogeneity could reduce the effectiveness of nanoparticles, creating difficulties in targeting to cancer cells due to differences between them based on permeability and vascular structure.In either case, nanoparticles may be cleared too

soon or they may accumulate within the non-target organs, which really in return would pose negative efficacy or toxicity [32]

Combined with the other major challenges, overcoming tumor heterogeneity and treatment resistance, which are both common to tumors of the gastrointestinal tract and breast cancer, have also been identified as major challenges. For example, certain populations of tumor cells overexpress some proteins or display distinctive genetic alterations that lead to resistance specifically to standard treatment. The absence of estrogen, progesterone, and HER2 receptors in TNBC makes it very difficult for treatment, requiring the development of directed therapies tailored to overcome such issues. Because drug resistance mechanisms like P-glycoprotein-mediated drug efflux may reduce the effectiveness of drug delivery to tumor sites by nanoparticles, more comprehensive nanoparticle designs that eventually abolish resistance are to be considered. Nanoparticle detection by the immune system as a marker for foreign body waste may actually be destroyed before reaching the tumor, adding even more complication to the Immune System response to nanoparticles. This could greatly diminish the therapeutic advantage of nanoparticles if they are eliminated from circulation by macrophages, e.g. dendritic cells. Nanoparticle surface modifications will, therefore, be required to abate the immunological recognition and improve circulation time toward enhanced targeting.

Though these obstacles stand, the future with nanoparticle-based treatment applications in cancer therapy looks pretty bright. One of the hopeful schemes for better outcomes of treatment is creating customized and perfectly focused nanomedicine. Treatments can then be less toxic but much effective through modification of the therapeutic nanoparticles in targeting the specific cancer cell of the appropriate molecular nature of the tumor. For instance, nanoparticles can be functionalized with targeting ligands to specifically target receptors on the cancer cells, such as the EGFR for colorectal cancer or HER2 for breast cancer, thus enhancing medication administration precision. Many of the nanoparticle-based combinatorial therapies can exert a synergistic effect by redirects through a different pathway of cancer growth. Chemotherapy, immunotherapy, or gene therapy delivered in nanoparticle formulations can target cancer cells from several angles and overcome tumor heterogeneity and drug resistance. The therapy given is tracked through an effective method for delivery, and at the same time, various cells in tumors are targeted through theranostics, which give therapeutic and diagnostic properties in a single nanoparticle. Stimuli-responsive nanoparticles are also promising with regard to improving treatment results while minimizing adverse outcomes, such as releasing the medication under defined triggers like pH or temperature present within the tumor's microenvironment.

Conclusion:

Nanoparticles are indeed greatly useful for cancer therapy, particularly in breast cancer and colorectal cancer. Target therapy is the method that minimize the side effects on the system and maximizes its therapeutic effect. Nanoparticles have such capability that it directly delivers drugs to tumor sites for site-specific therapy. Drug resistance and tumor heterogeneity are common problems that can be efficiently addressed using personalized medicine, combination therapy, and targeted drug delivery. Several barriers will have to be surmounted first by nanoparticles for their therapeutic interventions to become fully integrated into clinical practice; for example, biocompatibility, toxicity, immune system interactions, and scalability of production. Hence, for optimal nanoparticle design, enhancing safety profiles, and application in cancer treatment, there is a continuous need for research in this area. As it develops, nanotechnology and reduced-scale medicine are really going to make a difference in the lives of patients, delivering personalized, effective, and targeted therapies. Oncology nanomedicine certainly has a bright future, but it has to navigate several current challenges to

develop safer and more effective solutions to cancer.

References

1. Jain, K.K. (2005). Nanotechnology in the pharmaceutical sciences. *Journal of Nanoscience and Nanotechnology*, 5(3), 366-372.
2. Allen, T.M., & Cullis, P.R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36-48.
3. Alrushaid N, Khan FA, Al-Suhaimi EA, Elaissari A. Nanotechnology in cancer diagnosis and treatment. Pharmaceutics. 2023 Mar 22;15(3):1025.
4. Jain, R. K. (2001). *Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression in tumors*. Journal of Clinical Investigation, 108(8), 115-121.
5. Barenholz, Y. (2012). *Liposome application: Problems and prospects*. Nano Today, 7(2), 122-135.
6. Jiang, W., et al. (2013). *Gold nanomaterials in cancer therapy: Opportunities and challenges*. Future Medicinal Chemistry, 5(1), 87-106.
7. Nicolini, A., et al. (2013). *Nanoparticles in cancer therapy and drug delivery systems*. Nanomedicine, 8(4), 526-540.
8. Duncan, R. (2003). *The dawning era of polymer therapeutics*. Nature Reviews Drug Discovery, 2(5), 347-360.
9. Sharma, A., et al. (2015). *Colorectal cancer in India: A review of the changing epidemiology and challenges*. Indian Journal of Gastroenterology, 34(4), 233-239.
10. Indian Council of Medical Research. (2016). Colorectal Cancer in India.
11. Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacology & therapeutics. 2020 Feb 1;206:107447.
12. Ghosh, P., et al. (2015). *Nanotechnology in cancer therapy: A review*. European Journal of Pharmaceutical Sciences, 76, 22-39.
13. Rejhová A, Opattová A, Čumová A, Slíva D, Vodička P. Natural compounds and combination therapy in colorectal cancer treatment. European journal of medicinal chemistry. 2018 Jan 20;144:582-94.
14. Zhang, Y., et al. (2016). *Gene delivery using nanoparticles in cancer therapy*. Cancer Gene Therapy, 23(9), 431-441.
15. Miller, D. A., et al. (2016). *Nanoparticle-based immunotherapy for colorectal cancer*. Journal of Clinical Immunotherapy, 22(6), 1234-1243.
16. Yu X, Fang C, Zhang K, Su C. Recent advances in nanoparticles-based platforms targeting the PD-1/PD-L1 pathway for cancer treatment. Pharmaceutics. 2022 Jul 29;14(8):1581.
17. Chandran, R., et al. (2015). *Gold nanoparticles in cancer therapy and drug delivery systems*. Nanomedicine, 10(9), 1341-1355.
18. Tada DB, Baptista MS. Photosensitizing nanoparticles and the modulation of ROS generation. Frontiers in chemistry. 2015 May 27;3:33.
19. Ghorbani F, Kokhaei P, Ghorbani M, Eslami M. Application of different nanoparticles in the diagnosis of colorectal cancer. Gene Reports. 2020 Dec 1;21:100896.
20. Gogoi P, Kaur G, Singh NK. Nanotechnology for colorectal cancer detection and treatment. World journal of gastroenterology. 2022 Dec 14;28(46):6497.
21. Shaath H, Elango R, Alajez NM. Molecular classification of breast cancer utilizing long non-coding RNA (lncRNA) transcriptomes identifies novel diagnostic lncRNA panel for triple-negative breast cancer. Cancers. 2021 Oct 26;13(21):5350.
22. Miele, L., et al. (2017). *Targeted nanoparticles in cancer immunotherapy*. Journal of Clinical Investigation, 127(3), 984-992.
23. Adel M, Zahmatkeshan M, Akbarzadeh A, Rabiee N, Ahmadi S, Keyhanvar P, Rezayat

SM, Seifalian AM. Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles. Biotechnology Reports. 2022 Jun 1;34: e00730.
24. Li H, Prever L, Hirsch E, Gulluni F. Targeting PI3K/AKT/mTOR signaling pathway in breast cancer. Cancers. 2021 Jul 14;13(14):3517.
25. Bahreyni A, Mohamud Y, Luo H. Emerging nanomedicines for effective breast cancer immunotherapy. Journal of nanobiotechnology. 2020 Dec;18:1-4.
26. Ni J, Song J, Wang B, Hua H, Zhu H, Guo X, Xiong S, Zhao Y. Dendritic cell vaccine for the effective immunotherapy of breast cancer. Biomedicine & Pharmacotherapy. 2020 Jun 1;126:110046.
27. Sanna, V., et al. (2014). *Nanomedicine and targeted drug delivery in breast cancer*. Cancer Nanotechnology, 28(7), 123-133.
28. Aminolroayaei F, Shahbazi-Gahrouei S, Khorasani A, Shahbazi-Gahrouei D. A review of imaging methods and recent nanoparticles for breast cancer diagnosis. Information. 2023 Dec 22;15(1):10.
29. Alshareeda AT, Khatijah MN, Al-Sowayan BS. Nanotechnology: A revolutionary approach to prevent breast cancer recurrence. Asian Journal of Surgery. 2023 Jan 1;46(1):13-7.
30. Wakaskar RR. General overview of lipid–polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. Journal of drug targeting. 2018 Apr 21;26(4):311-8.
31. Sakhi M, Khan A, Iqbal Z, Khan I, Raza A, Ullah A, Nasir F, Khan SA. Design and characterization of paclitaxel-loaded polymeric nanoparticles decorated with trastuzumab for the effective treatment of breast cancer. Frontiers in Pharmacology. 2022 Mar 14;13:855294.
32. Guo, X., & Huang, L. (2011). Recent advances in nonviral vectors for gene delivery. *Accounts ofChemical Research*, *45*(7), 971–979. https://doi.org/10.1021/ar200151m